Nonsporulating clinical isolate identified as Petromyces alliaceus (anamorph Aspergillus alliaceus) by morphological and sequence-based methods.
Concerted morphological and sequencing-based strategies revealed the identity of a nonsporulating clinical isolate as Petromyces alliaceus (anamorph Aspergillus alliaceus). This rare Aspergillus sp. was recovered as the etiological agent of invasive pulmonary aspergillosis and had reduced in vitro susceptibilities to amphotericin B and caspofungin, which correlated with clinical failure of therapy.
Balajee
S Arunmozhi
SA
Mycotic Diseases Branch, Centers for Disease Control and Prevention, Mail Stop-G 11, 1600 Clifton Road, Atlanta, GA 30333, USA. fir3@cdc.gov
Lindsley
Mark D
MD
Iqbal
Naureen
N
Ito
James
J
Pappas
Peter G
PG
Brandt
Mary E
ME
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000494:pharmacology; D001229:Aspergillosis, Allergic Bronchopulmonary / Q000188:drug therapy / Q000382:microbiology*; D001230:Aspergillus / Q000166:cytology* / Q000187:drug effects / Q000235:genetics* / Q000302:isolation & purification; D000077336:Caspofungin; D004271:DNA, Fungal / Q000737:chemistry / Q000235:genetics; D004275:DNA, Ribosomal / Q000737:chemistry / Q000235:genetics; D021903:DNA, Ribosomal Spacer / Q000737:chemistry / Q000235:genetics; D054714:Echinocandins; D005260:Female; D006801:Humans; D055666:Lipopeptides; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008969:Molecular Sequence Data; D010456:Peptides, Cyclic / Q000494:pharmacology; D012339:RNA, Ribosomal, 28S / Q000235:genetics; D017422:Sequence Analysis, DNA; D012689:Sequence Homology, Nucleic Acid
D000935:Antifungal Agents; D004271:DNA, Fungal; D004275:DNA, Ribosomal; D021903:DNA, Ribosomal Spacer; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D012339:RNA, Ribosomal, 28S; D000666:Amphotericin B; D000077336:Caspofungin